Inventor
NICOLAS POIRIER
Inventor
FR
Overview
Patents· 18 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides27%
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
C12NMicroorganisms or enzymes8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
G06QInformation and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes2%
H04LTransmission of digital information, e.g. telegraphic communication2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
12,534,533Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applications202612,448,454Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof202512,371,502Antibodies directed against CD127202512,331,115Uses of anti-SIRPg antibodies202512,335,349Computing network system and method202512,331,118Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment202512,258,577Method effector cells using anti-CD127 antibodies for applications in cell therapy202512,252,546Anti-SIRPa antibodies and their therapeutic applications202512,091,464Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)202412,077,820Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients202411,926,671Antibodies and polypeptides directed against CD127202411,884,723Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies202411,713,356Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer202311,440,964Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody202211,365,257Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)202211,352,430Humanized anti-human-PD-1 antibody and its use in cancer treatment202211,279,766Anti-SIRPa antibodies and their therapeutic applications202211,230,602Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to OSE IMMUNOTHERAPEUTICS (17)· patent assignee history
2022–2025Patents assigned to INST NAT SANTE RECH MED (3)· patent assignee history
2022–2025Patents assigned to UNIV NANTES (3)· patent assignee history
2022–2026Based in FR· patent location history
2025Patents assigned to AMADEUS SAS (1)· patent assignee history
2025Patents assigned to ASSIST PUBLIQUE—HOPITAUX DE PARIS (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | 17 | 2022–2026 |
| INST NAT SANTE RECH MED | 3 | 2022–2025 |
| UNIV NANTES | 3 | 2022–2025 |
| AMADEUS SAS | 1 | 2025 |
| ASSIST PUBLIQUE—HOPITAUX DE PARIS | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| FR | 18 | 2022–2026 |